fda approval tirzepatide weight loss history The US-FDA has approved Tirzepatide for chronic management in adults with Obesity F.D.A. Approves New Obesity Drug

There is provider inertia where providers may not be thinking about it, Pantalone said of factors contributing to low screening rates

Supervision by healthcare providers is crucial when using these medications

Injectables require refrigeration, which may be challenging for patients without stable housing, privacy, or climate control

While injectable medications often yield more weight loss, the ease of oral options like Wegovy or Foundayo appeals to many

Additionally, higher doses of GLP-1 RAs (RR 1.63, 95% CI 1.112.40) and higher baseline BMI (RR 1.60, 95% CI 1.042.48) might significantly increase the risk of VAs